en
Scientific article
Open access
English

A bosentan pharmacokinetic study to investigate dosing regimens in paediatric patients with pulmonary arterial hypertension: FUTURE-3

Published inBritish Journal of Clinical Pharmacology, vol. 83, no. 8, p. 1734-1744
Publication date2017
Abstract

The aim of the present study was to investigate whether increasing the bosentan dosing frequency from 2 mg kg-1 twice daily (b.i.d.) to 2 mg kg-1 three times daily (t.i.d.) in children with pulmonary arterial hypertension (PAH) (from ≥3 months to <12 years of age) would increase exposure.

Keywords
  • Administration
  • Oral
  • Antihypertensive Agents/pharmacokinetics/therapeutic use
  • Area Under Curve
  • Child
  • Child
  • Preschool
  • Dose-Response Relationship
  • Drug
  • Drug Administration Schedule
  • Endothelin Receptor Antagonists/pharmacokinetics/therapeutic use
  • Female
  • Humans
  • Hypertension
  • Pulmonary/drug therapy
  • Infant
  • Male
  • Prospective Studies
  • Sulfonamides/pharmacokinetics/therapeutic use
Citation (ISO format)
BERGER, Rolf M F et al. A bosentan pharmacokinetic study to investigate dosing regimens in paediatric patients with pulmonary arterial hypertension: FUTURE-3. In: British Journal of Clinical Pharmacology, 2017, vol. 83, n° 8, p. 1734–1744. doi: 10.1111/bcp.13267
Main files (1)
Article (Published version)
Identifiers
ISSN of the journal0306-5251
492views
148downloads

Technical informations

Creation09/05/2018 12:24:00 PM
First validation09/05/2018 12:24:00 PM
Update time03/15/2023 8:37:11 AM
Status update03/15/2023 8:37:10 AM
Last indexation02/12/2024 12:53:56 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack